Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Antibiotics

New antibiotic effective against multi-drug resistant Gram-negative UTI

Researchers conclude that cefiderocol, which is also being trialled in lung and blood infections, could be used to overcome Gram-negative resistance.

Urine dipstick test

Source: Shutterstock.com

Among those who tested positive for a Gram-negative uropathogen, 73% in the cefiderocol group and 55% in the imipenem-cilastatin group were considered cured after treatment, indicating that cefiderocol is at least as effective as imipenem-cilastatin

A new antibiotic designed to overcome multi-drug resistance is at least as effective as the current standard of care in complicated urinary tract infection (UTI), according to trial results published in The Lancet Infectious Diseases (25 October 2018)[1].

The trial randomly assigned 303 people to an intravenous infusion of new antibiotic cefiderocol and 149 to the standard of care imipenem-cilastatin, three times daily for 7–14 days.

Among those who tested positive for a Gram-negative uropathogen at baseline, 73% in the cefiderocol group and 55% in the imipenem-cilastatin group were considered cured after treatment, indicating non-inferiority of cefiderocol. There were also fewer adverse events in the cefiderocol group compared with standard care.

Cefiderocol is a cephalosporin antibiotic that contains a siderophore side chain. This component helps the antibiotic overcome the resistance mechanisms evolved by Gram-negative bacteria to existing antibiotics by hijacking the bacteria’s iron transport mechanism to gain entry to the cell.

The researchers said the findings indicate the promise of the drug, which is also being trialled in lung and blood infections, including in carbapenem-resistant infections.

“As a siderophore antibiotic, cefiderocol is a novel approach that might be used to overcome Gram-negative resistance,” the authors concluded.

Citation: Clinical Pharmacist DOI: 10.1211/CP.2018.20205740

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.